TG Therapeutics announced that its ex-US partner, Neuraxpharm Group launched BRIUMVI in Europe, for the treatment of adults patients with relapsing forms of multiple sclerosis, who have active disease defined by clinical or imaging features. The launch commenced in Germany, with additional launches throughout Europe to follow. In accordance with the ex-US commercialization agreement, TG Therapeutics will receive a milestone payment of $12.5 million for the first launch of BRIUMVI in a European country.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on TGTX:
- TGTX Upcoming Earnings Report: What to Expect?
- TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2023 Financial Results and Business Update
- TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
- Precision gets initial $7.5M from TG Therapeutics for azer-cel development
- TG Therapeutics participates in a conference call with Cantor Fitzgerald
